Skip to content

HLA Eplet Mismatches to Predict Long-term Kidney Transplant Outcomes

Prognostic Value of HLA Eplet Mismatches for Long-term Kidney Transplant Outcomes

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07269275
Enrollment
5525
Registered
2025-12-08
Start date
2023-01-01
Completion date
2025-07-01
Last updated
2025-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplant Failure

Keywords

graft survival, kidney function, prediction, kidney transplantation

Brief summary

Human leukocyte antigen (HLA) matching evaluates the degree of compatibility between donors and organ transplant recipients and assesses broad antigen differences that may influence immune responses post-transplant. A refined HLA matching method based on examining clusters of amino acids on HLA molecules, named eplets, has been recently developed. This method identifies immunogenic discrepancies that may not be apparent through traditional HLA matching. In recent years, assessment of HLA eplet mismatches has emerged as a promising strategy to improve immune risk stratification in kidney transplantation, which is crucial for kidney recipients' management and maximizing allograft longevity. Despite its potential, the prognostic value and clinical relevance of HLA eplet mismatches for predicting long-term kidney allograft failure has not been robustly demonstrated. In this study, the investigators aim to investigate whether HLA eplet mismatches may represent a relevant clinical tool for patient risk stratification and prediction of long-term allograft failure beyond standard clinical, histological and immunological parameters for monitoring in kidney transplant recipients.

Interventions

OTHERNo intervention

No intervention

Sponsors

Paris Translational Research Center for Organ Transplantation
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Living or deceased donor kidney recipients transplanted after 2004 * Kidney recipients older than 18 years of age * Kidney recipients with available HLA genotyping data

Exclusion criteria

* Combined transplantation

Design outcomes

Primary

MeasureTime frame
Kidney allograft failureUp to 10 years after kidney transplantation

Secondary

MeasureTime frameDescription
Added prognostic valueUp to 10 years after kidney transplantationAdded prognostic value of HLA eplet mismatches over standard of care monitoring of kidney transplant recipients based on clinical, histological, immunological parameters

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026